NCT04060550View on ClinicalTrials.gov

Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum

UnknownOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

January 9, 2020

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions
Atopic Dermatitis With a History of Eczema HerpeticumAtopic Dermatitis Without a History of Eczema HerpeticumHealth Controls Without Atopy
Interventions
BIOLOGICAL

Xolair

This is in vitro mechanistic study. No drug will be given in vivo to patients.

Trial Locations (1)

80206

RECRUITING

National Jewish Health, Denver

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

National Jewish Health

OTHER